semaglutide
Research Roundup
Debbie Rigby rounds up the latest research news Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 …
Shortages, discontinuations seeing people on multiple medications
Semaglutide scarcity and other similar shortages have led to people doubling up on treatments, says diabetes educator and pharmacist Medicines shortages and discontinuations are leading to people concurrently taking multiple …
Oral versions of GLP-1s on the horizon
With benefits beyond glucose control for the “new kid on the block” in diabetes management, leading researcher foreshadows oral versions with less side effects New versions of GLP-1 receptor agonists …
Telehealth provider pays $198k ad fine
Midnight Health enters voluntary enforceable undertaking after being handed 10 infringement notices relating to breaches of the Therapeutic Goods Act 1989 The Therapeutic Goods Administration (TGA) has confirmed that Midnight …
Renewed PBS bid for Wegovy
PBAC to consider semaglutide listing for new indication of established CVD with obesity The PBAC will soon consider whether Novo Nordisk’s Wegovy (semaglutide 2.4mg) should be subsidised for Australians with …
Border Force intercepts counterfeit semaglutide
Regulator issues warning after a shipment of substandard semaglutide was seized at the border Health practitioners and patients are being urged to be aware of the potential risks posed by …
Compounder enters enforceable undertaking over semaglutide ads
Compounding pharmacy group enters three-year court-enforceable undertaking after regulator flags concerns over alleged promotion of compounded weight-loss treatments Your Solution Compounding Pharmacy accepts “its website likely unlawfully promoted the use …
Call to PBS list weight loss jabs
Manufacturers of GLP-1 RAs such as semaglutide are being urged to invest in listing the medications on the PBS to treat obesity The Royal Australian College of General Practitioners is …
Butler holds firm on semaglutide compounding ban
Government says ‘no’, to lifting ban on compounding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) Risks associated with compounded GLP-1 RAs outweigh the benefits of improved access to the medication, Mark …
Confusion with Wegovy prescriptions
PDL offers advice for pharmacists regarding Wegovy (semaglutide) following a number of incident reports Pharmacists are likely aware that Wegovy (semaglutide) is now available in Australia. The PDL Professional Officers …
Wegovy’s arrival provides Ozempic alternative for weight management
Supplies of Ozempic (semaglutide) should be prioritised for type 2 diabetes patients the TGA says, as sponsor Novo Nordisk, launches its Wegovy brand for weight loss Pharmacists and prescribers are …
Ozempic shortages to continue: Butler
Novo Nordisk “simply doesn’t have the factories” to meet growing demand for Ozempic, Health Minister says Shortages of Novo Nordisk’s diabetes medication, Ozempic (semaglutide) are likely to continue into 2025, …